Jakafi

intermediate risk Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera + 10 more

Treatment

11 FDA approvals

20 Active Studies for Jakafi

Treatment for

intermediate risk Myelofibrosis

What is Jakafi

RuxolitinibThe Generic name of this drug

Treatment SummaryRuxolitinib, also known as Jakafi, is a drug used to prevent cell growth and treat certain types of blood cancer and other immune system diseases. It was first approved by the FDA in 2011 and is used to treat myelofibrosis and polycythemia vera. In 2019, it was also approved for use in adults and children with steroid-refractory acute graft-versus-host disease, and in 2021 for mild to moderate atopic dermatitis. Ruxolitinib works by blocking the JAK1 and JAK2 tyrosine kinases responsible for cytokine signalling and he

Jakafiis the brand name

image of different drug pills on a surface

Jakafi Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Jakafi

Ruxolitinib

2011

Approved as Treatment by the FDA

Ruxolitinib, otherwise called Jakafi, is approved by the FDA for 11 uses like Disease and Graft-vs-Host Disease .

Disease

Helps manage Chronic Graft Versus Host Disease

Graft-vs-Host Disease

Helps manage Acute Graft-Versus-Host Disease (GVHD)

Polycythemia Vera

Helps manage refractory Polycythemia vera

Polycythemia

Helps manage Post Polycythemia Vera Myelofibrosis

Steroid Refractory

Helps manage Steroid Refractory

Primary Myelofibrosis

Helps manage Post Essential Thrombocythaemia Myelofibrosis

resistant to or intolerant of hydroxyurea

Helps manage resistant to or intolerant of hydroxyurea

failure of at least one prior systemic therapy

Helps manage failure of at least one prior systemic therapy

intermediate risk Myelofibrosis

Helps manage intermediate risk Myelofibrosis

Primary Myelofibrosis

Helps manage Primary Myelofibrosis (PMF)

Primary Myelofibrosis

Helps manage high risk Myelofibrosis

Effectiveness

How Jakafi Affects PatientsRuxolitinib is a medicine used to treat different kinds of blood cancer. It works by stopping cells from growing and dividing, killing cancer cells, and lowering inflammation in the body. In clinical trials, ruxolitinib was found to reduce the size of the spleen and improve symptoms of myelofibrosis. Studies on mice have also shown that it can help extend the lifespan of those with myeloproliferative neoplasms. Ruxolitinib works by blocking a protein called JAK2, which is found in both normal cells and cancer cells. However, some cancers, such as those with

How Jakafi works in the bodyThe Janus kinase (JAK) family of proteins helps control the way the body responds to growth factors and cytokines. These proteins are important for lymphocyte development and help regulate gene expression of pro-inflammatory cytokines. Ruxolitinib is a drug that blocks certain JAK proteins, thus preventing the body from responding in an excessive way to these cytokines and growth factors. In cancer cells, this can lead to cell death. This drug is also used to treat graft-versus-host-disease, an immune complication of allogeneic hematopoietic cell transplantation.

When to interrupt dosage

The advised dosage of Jakafi is contingent upon the recognized condition, including reluctance to or insensitivity to hydroxyurea, Steroid Refractory and Primary Myelofibrosis. Dosage varies according to the technique of administration (e.g. Cream - Topical or Oral) noted in the table below.

Condition

Dosage

Administration

intermediate risk Myelofibrosis